CompletedPhase 1NCT01224639

Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever

Studying Dengue fever

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Inviragen Inc.
Principal Investigator
Ivan D Velez, MD, Ph.D.
PECET, Universidad the Antioquia, Medellin, Colombia
Intervention
TDV - Low Dose(biological)
Enrollment
96 enrolled
Eligibility
18-45 years · All sexes
Timeline
2010 – 2011

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01224639 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials